De Ritis比值与卒中患者28 d病死率的关联:一项MIMIC-Ⅳ数据库分析

doi:10.3969/j.issn.1004-583X.2025.11.003

摘要/Abstract

摘要：

目的探究天冬氨酸转氨酶/丙氨酸转氨酶(De Ritis比值)在脑卒中患者中28 d病死率的影响关联,并分析合并不同疾病后其具体预测价值。方法采用回顾性队列研究提取MIMIC-Ⅳ数据库(2008-2019年)中6 165例脑卒中患者(ICD编码:I60/I63/I69),经缺失值筛选后最终纳入1 674例。缺失数据采用均值插补,缺失率>20%的变量被剔除。通过LASSO回归筛选变量,建立多变量Cox比例风险模型(含限制性立方样条函数)评估De Ritis比值与病死率的关系,并调整SOFA/APACHE-Ⅱ评分、器官支持及生物标志物等混杂因素。模型性能通过ROC-AUC和校准度验证,并预设亚组分析检验合并症的修饰效应。结果 De Ritis ratio是28 d病死率的独立预测因子。Kaplan-Meier分析表明,De Ritis最高组(Q4)生存率显著低于其他组(P<0.01)。单因素Cox回归证实,随De Ritis升高,死亡风险递增,其中Q3组HR=2.073(95%CI: 1.477~2.91, P<0.01),Q4组HR=2.066(95%CI: 1.452~2.939, P<0.01)。多因素模型(AUC=0.764)进一步验证其独立性。非线性分析揭示关键转折点(De Ritis=2):比值≤2时死亡风险随比值上升而增加,>2时影响不确定性升高。决策曲线证实其在广泛阈值概率具有临床净效益。亚组分析提示,该比值对高龄、无急性肾损伤/肝硬化/冠心病患者的预测价值更显著。结论 De Ritis比值是一种潜在的、有前景的预后指标,可用于评估脑卒中患者的死亡风险,为临床医生提供更准确的预后信息,从而帮助优化治疗策略,改善患者预后。

关键词: 卒中, De Ritis比值, MIMIC-Ⅳ数据库

Abstract:

Objective To evaluate the association between the aspartate transaminase (AST)/alanine transaminase (ALT) (De Ritis) ratio and 28-day mortality in patients with cerebrovascular accident (stroke) and to assess its predictive value across clinical subgroups. Methods We performed a retrospective cohort study using the MIMICIV database (2008-2019). From 6, 165 stroke admissions identified by ICD codes I60, I63, and I69, 1, 674 patients were retained after excluding cases with excessive missing data. Missing values were imputed by mean substitution; variables with >20% missingness were excluded. Candidate predictors were selected using LASSO regression. A multivariable Cox proportional hazards model-including restricted cubic splines to evaluate nonlinearity-was used to estimate the association between the De Ritis ratio and 28-day mortality, adjusting for potential confounders such as Sequential Organ Failure Assessment (SOFA)/Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) scores, organ support measures, and relevant biomarkers. Model discrimination and calibration were assessed using ROC-AUC and calibration plots. Preplanned subgroup analyses explored effect modification by comorbidities. Results The De Ritis ratio was an independent predictor of 28-day mortality. KaplanMeier analysis showed significantly lower survival in the highest quartile (Q4) compared with lower quartiles (P<0.01). In univariate Cox models, mortality risk increased with higher De Ritis quartiles (Q3: HR=2.073, 95%CI: 1.477-2.91; Q4: HR=2.066, 95%CI: 1.452-2.939; both P<0.01). The multivariable model retained the De Ritis ratio as an independent predictor and achieved an AUC of 0.764. Restricted cubic spline analysis identified an inflection point at a De Ritis ratio of approximately 2: Risk increased with rising ratio up to 2, while the relationship beyond 2 was less consistent. Decision curve analysis demonstrated clinical net benefit across a wide range of threshold probabilities. Subgroup analyses indicated stronger predictive value in older patients and in those without acute kidney injury, cirrhosis, or coronary artery disease. Conclusion The De Ritis (AST/ALT) ratio is a promising prognostic biomarker for stroke. It may help clinicians better estimate shortterm mortality risk, inform treatment decisions, and ultimately improve patient outcomes.

Key words: stroke, De Ritis ratio, MIMIC-Ⅳ database

中图分类号:

R743

任德志, 徐斯瑶, 王帅, 段军. De Ritis比值与卒中患者28 d病死率的关联:一项MIMIC-Ⅳ数据库分析[J]. 临床荟萃, 2025, 40(11): 978-987.

Ren Dezhi, Xu Siyao, Wang Shuai, Duan Jun. Association between the De Ritis ratio and 28-day mortality in patients with cerebrovascular accident: A MIMIC-Ⅳ database analysis[J]. Clinical Focus, 2025, 40(11): 978-987.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2025.11.003

https://www.lchc.cn/CN/Y2025/V40/I11/978

图/表 9

图1 纳入和排除程序以及定量分组的流程图

Fig.1 Flowchart of inclusion and exclusion procedures and quantitative grouping

表1 各组患者一般临床资料比较

Tab.1 Baseline characteristics between groups

项目	总体	Q1:0.791(0~1.037)	Q2:1.219(1.038~1.426)	Q3:1.675(1.429~2.000)	Q4: 2.462(2.000~3.429)	$P$ 值
例数	1 674	432	421	454	367
年龄(岁)	72(22~104)	69(22~104)	73(27~93)	74(24~104)	73(26~97)	<0.01
BMI(kg/m²)	27.257(12.24~95.84)	28.439(14.06~61.592)	27.218(14.985~95.84)	26.607(16.005~50.529)	26.91(12.24~54.444)	0.013
性别[例(%)]
女性男性	700(41.82) 974(58.18)	157(36.34) 275(63.66)	179(42.52) 242(57.48)	188(41.41) 266(58.59)	176(47.96) 191(52.04)	0.011
CRRT天数(d)	0(0~33)	0(0~17)	0(0~32)	0(0~24)	0(0~33)	0.034
生命体征
HR(次/min)	85(28~166)	85(28~148)	85(41~150)	85.5(39~154)	86(37~166)	0.581
平均动脉压(mmHg)	85.667(33.333~210.667)	91.333(40.667~149.667)	85.5(33.333~210.667)	84.667(37~198.667)	80.833(33.667~175.333)	<0.01
RR(次/min)	18(0~73)	19(0~50)	18(0~48)	18(0~40)	18(0~73)	0.828
温度(°F)	98.1(34.9~106)	98.2(92.4~103.1)	98.1(34.9~104.3)	98.2(93~103.9)	98.1(85.4~106)	0.105
评分系统(分)
OASIS	34(10~72)	32(15~72)	34(10~60)	36(15~64)	36(15~58)	<0.01
SAPSⅡ	40(9~98)	36(9~98)	39(13~88)	41(13~93)	42(15~90)	<0.01
CHARLSON	6(0~17)	6(0~14)	6(0~15)	7(0~17)	6(0~16)	0.001
SOFA	5(0~20)	4(0~17)	5(0~17)	6(0~18)	6(0~20)	<0.01
GCS	15(3~15)	15(3~15)	15(3~15)	15(3~15)	15(3~15)	0.651
APACHEⅡ	19(2~49)	17(2~49)	18(5~45)	19.5(4~48)	21(7~48)	<0.01
合并症
心肌梗死[例(%)]
否是	1 497(89.43) 177(10.57)	393(90.97) 39(9.03)	384(91.21) 37(8.79)	404(88.99) 50(11.01)	316(86.10) 51(13.90)	0.076
高血压[例(%)]
否是	913(54.54) 761(45.46)	229(53.01) 203(46.99)	214(50.83) 207(49.17)	261(57.49) 193(42.51)	209(56.95) 158(43.05)	0.158
肝硬化[例(%)]
否是	1 587(94.80) 87(5.20)	427(98.84) 5(1.16)	408(96.91) 13(3.09)	427(94.05) 27(5.95)	325(88.56) 42(11.44)	<0.001
2型糖尿病[例(%)]
否是	1 056(63.08) 618(36.92)	271(62.73) 161(37.27)	258(61.28) 163(38.72)	305(67.18) 149(32.82)	222(60.49) 145(39.51)	0.176
COPD[例(%)]
否是	1 350(80.65) 324(19.35)	356(82.41) 76(17.59)	331(78.62) 90(21.38)	369(81.28) 85(18.72)	294(80.11) 73(19.89)	0.542
心力衰竭[例(%)]
否是	1 012(60.45) 662(39.55)	277(64.12) 155(35.88)	269(63.90) 152(36.10)	255(56.17) 199(43.83)	211(57.49) 156(42.51)	0.025
实验室参数
血红蛋白(g/dl)	10.5(4.6~20)	11(5~16.3)	10.8(4.6~18.6)	10.2(4.8~20)	9.9(4.7~17.2)	<0.01
RBC(×10¹²/L)	3.53(1.15~7.25)	3.77(1.52~6.17)	3.635(1.54~6.2)	3.42(1.45~5.82)	3.32(1.15~7.25)	<0.01
WBC(×10⁹/L)	11.3(0.1~59.7)	10.8(0.1~59.7)	11.65(0.3~52.3)	11(0.6~56.3)	11.9(0.6~47)	0.317
白蛋白(g/dl)	3.1(1.1~4.9)	3.2(1.2~4.9)	3.1(1.5~4.7)	3.1(1.1~4.9)	3(1.4~4.9)	<0.01
pH值	7.38(6.89~7.65)	7.39(6.95~7.59)	7.38(6.98~7.61)	7.39(6.97~7.56)	7.37(6.89~7.65)	0.004
凝血酶原时间(s)	14.4(8.9~150)	13.7(9.3~124.6)	14(10.4~92.2)	14.9(10.1~150)	15.1(8.9~84.5)	0.015
总胆红素(mg/dl)	0.6(0.1~31.3)	0.5(0.1~22)	0.5(0.1~14)	0.6(0.1~20.5)	0.6(0.1~31.3)	0.003
BUN(mg/dl)	22(3~212)	23(6~212)	21(5~139)	23(5~200)	22(3~159)	0.236
血小板计数(×10⁹/L)	193(5~1647)	200(31~796)	204(16~855)	189(5~1592)	165(17~1647)	<0.01
SIRS[例(%)]
0	18(1.08)	6(1.39)	3(0.71)	7(1.54)	2(0.54)
1	168(10.04)	55(12.73)	45(10.69)	45(9.91)	23(6.27)
2	495(29.57)	134(31.02)	126(29.93)	140(30.84)	95(25.89)	0.029
3	677(40.44)	169(39.12)	174(41.33)	175(38.55)	159(43.32)
4	316(18.88)	68(15.74)	73(17.34)	87(19.16)	88(23.98)

表1 各组患者一般临床资料比较

Tab.1 Baseline characteristics between groups

项目	总体	Q1:0.791(0~1.037)	Q2:1.219(1.038~1.426)	Q3:1.675(1.429~2.000)	Q4: 2.462(2.000~3.429)	$P$ 值
例数	1 674	432	421	454	367
年龄(岁)	72(22~104)	69(22~104)	73(27~93)	74(24~104)	73(26~97)	<0.01
BMI(kg/m²)	27.257(12.24~95.84)	28.439(14.06~61.592)	27.218(14.985~95.84)	26.607(16.005~50.529)	26.91(12.24~54.444)	0.013
性别[例(%)]
女性男性	700(41.82) 974(58.18)	157(36.34) 275(63.66)	179(42.52) 242(57.48)	188(41.41) 266(58.59)	176(47.96) 191(52.04)	0.011
CRRT天数(d)	0(0~33)	0(0~17)	0(0~32)	0(0~24)	0(0~33)	0.034
生命体征
HR(次/min)	85(28~166)	85(28~148)	85(41~150)	85.5(39~154)	86(37~166)	0.581
平均动脉压(mmHg)	85.667(33.333~210.667)	91.333(40.667~149.667)	85.5(33.333~210.667)	84.667(37~198.667)	80.833(33.667~175.333)	<0.01
RR(次/min)	18(0~73)	19(0~50)	18(0~48)	18(0~40)	18(0~73)	0.828
温度(°F)	98.1(34.9~106)	98.2(92.4~103.1)	98.1(34.9~104.3)	98.2(93~103.9)	98.1(85.4~106)	0.105
评分系统(分)
OASIS	34(10~72)	32(15~72)	34(10~60)	36(15~64)	36(15~58)	<0.01
SAPSⅡ	40(9~98)	36(9~98)	39(13~88)	41(13~93)	42(15~90)	<0.01
CHARLSON	6(0~17)	6(0~14)	6(0~15)	7(0~17)	6(0~16)	0.001
SOFA	5(0~20)	4(0~17)	5(0~17)	6(0~18)	6(0~20)	<0.01
GCS	15(3~15)	15(3~15)	15(3~15)	15(3~15)	15(3~15)	0.651
APACHEⅡ	19(2~49)	17(2~49)	18(5~45)	19.5(4~48)	21(7~48)	<0.01
合并症
心肌梗死[例(%)]
否是	1 497(89.43) 177(10.57)	393(90.97) 39(9.03)	384(91.21) 37(8.79)	404(88.99) 50(11.01)	316(86.10) 51(13.90)	0.076
高血压[例(%)]
否是	913(54.54) 761(45.46)	229(53.01) 203(46.99)	214(50.83) 207(49.17)	261(57.49) 193(42.51)	209(56.95) 158(43.05)	0.158
肝硬化[例(%)]
否是	1 587(94.80) 87(5.20)	427(98.84) 5(1.16)	408(96.91) 13(3.09)	427(94.05) 27(5.95)	325(88.56) 42(11.44)	<0.001
2型糖尿病[例(%)]
否是	1 056(63.08) 618(36.92)	271(62.73) 161(37.27)	258(61.28) 163(38.72)	305(67.18) 149(32.82)	222(60.49) 145(39.51)	0.176
COPD[例(%)]
否是	1 350(80.65) 324(19.35)	356(82.41) 76(17.59)	331(78.62) 90(21.38)	369(81.28) 85(18.72)	294(80.11) 73(19.89)	0.542
心力衰竭[例(%)]
否是	1 012(60.45) 662(39.55)	277(64.12) 155(35.88)	269(63.90) 152(36.10)	255(56.17) 199(43.83)	211(57.49) 156(42.51)	0.025
实验室参数
血红蛋白(g/dl)	10.5(4.6~20)	11(5~16.3)	10.8(4.6~18.6)	10.2(4.8~20)	9.9(4.7~17.2)	<0.01
RBC(×10¹²/L)	3.53(1.15~7.25)	3.77(1.52~6.17)	3.635(1.54~6.2)	3.42(1.45~5.82)	3.32(1.15~7.25)	<0.01
WBC(×10⁹/L)	11.3(0.1~59.7)	10.8(0.1~59.7)	11.65(0.3~52.3)	11(0.6~56.3)	11.9(0.6~47)	0.317
白蛋白(g/dl)	3.1(1.1~4.9)	3.2(1.2~4.9)	3.1(1.5~4.7)	3.1(1.1~4.9)	3(1.4~4.9)	<0.01
pH值	7.38(6.89~7.65)	7.39(6.95~7.59)	7.38(6.98~7.61)	7.39(6.97~7.56)	7.37(6.89~7.65)	0.004
凝血酶原时间(s)	14.4(8.9~150)	13.7(9.3~124.6)	14(10.4~92.2)	14.9(10.1~150)	15.1(8.9~84.5)	0.015
总胆红素(mg/dl)	0.6(0.1~31.3)	0.5(0.1~22)	0.5(0.1~14)	0.6(0.1~20.5)	0.6(0.1~31.3)	0.003
BUN(mg/dl)	22(3~212)	23(6~212)	21(5~139)	23(5~200)	22(3~159)	0.236
血小板计数(×10⁹/L)	193(5~1647)	200(31~796)	204(16~855)	189(5~1592)	165(17~1647)	<0.01
SIRS[例(%)]
0	18(1.08)	6(1.39)	3(0.71)	7(1.54)	2(0.54)
1	168(10.04)	55(12.73)	45(10.69)	45(9.91)	23(6.27)
2	495(29.57)	134(31.02)	126(29.93)	140(30.84)	95(25.89)	0.029
3	677(40.44)	169(39.12)	174(41.33)	175(38.55)	159(43.32)
4	316(18.88)	68(15.74)	73(17.34)	87(19.16)	88(23.98)

图2 K-M曲线生存分析图

Fig.2 The Kaplan-Meier survival curve

图3 28 d病死率的Cox比例 H R

Fig.3 Cox proportional H R for 28-day mortality

图4 LASSO回归分析,lambda 1se=-4.508,lambda min=-7.113 a. Lasso 回归的系数路径图; b.Lasso 回归的交叉验证曲线

Fig.4 LASSO regression analysis, lambda 1se=-4.508, lambda min=-7.113 a.Lasso regression coefficients trajectory plot b.Lasso regression cross-validation plot

表2 CVA患者28 d病死率的多变量Cox回归分析

Tab.2 Multivariable Cox regression analysis for 28-day mortality in CVA patients

项目	数值	$H R$	95% $C I$		$P$ 值
项目	数值	$H R$	下限	上限	$P$ 值
年龄(岁)	70.87±13.71	1.03	1.018	1.043	0
BMI(kg/m²)	28.32±7.02	0.985	0.967	1.004	0.118
Na⁺	138.83±5.34	0.984	0.963	1.004	0.122
MAP(mmHg)	87.89±20.11	1.003	0.998	1.009	0.275
血红蛋白(mmol/L)	10.62±2.27	1.007	0.892	1.136	0.916
pH	7.36±0.09	0.381	0.12	1.213	0.102
血小板计数(×10⁹/L)	210.97±116.40	1	0.999	1.001	0.991
总胆红素	0.96±1.67	1.042	0.993	1.094	0.096
凝血酶原时间(s)	17.73±10.78	1.004	0.994	1.014	0.44
OASIS	34.69±8.60	1.023	1.003	1.043	0.023
APACHE Ⅱ	41.04±13.83	0.994	0.978	1.009	0.435
APS Ⅲ	50.21±21.74	1.009	1	1.018	0.044
Charlson	6.32±2.73	1.077	1.021	1.136	0.006
冠心病(例)
否是	911 763	0.9	0.703	1.152	0.402
急性肾衰竭(例)
否是	948 726	1	0.775	1.29	0.999
CRRT天数(d)	0.40±2.15	0.929	0.868	0.994	0.032
CRRT(例)
否是	1 549 125	3.443	2.201	5.387	0
SIRS(例)
0	18
1	168	0.334	0.121	0.917	0.033
2	495	0.37	0.147	0.929	0.034
3	677	0.367	0.147	0.914	0.031
4	316	0.723	0.288	1.816	0.49
机械通气(例)
否是	690 984	2.095	1.536	2.857	0

表2 CVA患者28 d病死率的多变量Cox回归分析

Tab.2 Multivariable Cox regression analysis for 28-day mortality in CVA patients

项目	数值	$H R$	95% $C I$		$P$ 值
项目	数值	$H R$	下限	上限	$P$ 值
年龄(岁)	70.87±13.71	1.03	1.018	1.043	0
BMI(kg/m²)	28.32±7.02	0.985	0.967	1.004	0.118
Na⁺	138.83±5.34	0.984	0.963	1.004	0.122
MAP(mmHg)	87.89±20.11	1.003	0.998	1.009	0.275
血红蛋白(mmol/L)	10.62±2.27	1.007	0.892	1.136	0.916
pH	7.36±0.09	0.381	0.12	1.213	0.102
血小板计数(×10⁹/L)	210.97±116.40	1	0.999	1.001	0.991
总胆红素	0.96±1.67	1.042	0.993	1.094	0.096
凝血酶原时间(s)	17.73±10.78	1.004	0.994	1.014	0.44
OASIS	34.69±8.60	1.023	1.003	1.043	0.023
APACHE Ⅱ	41.04±13.83	0.994	0.978	1.009	0.435
APS Ⅲ	50.21±21.74	1.009	1	1.018	0.044
Charlson	6.32±2.73	1.077	1.021	1.136	0.006
冠心病(例)
否是	911 763	0.9	0.703	1.152	0.402
急性肾衰竭(例)
否是	948 726	1	0.775	1.29	0.999
CRRT天数(d)	0.40±2.15	0.929	0.868	0.994	0.032
CRRT(例)
否是	1 549 125	3.443	2.201	5.387	0
SIRS(例)
0	18
1	168	0.334	0.121	0.917	0.033
2	495	0.37	0.147	0.929	0.034
3	677	0.367	0.147	0.914	0.031
4	316	0.723	0.288	1.816	0.49
机械通气(例)
否是	690 984	2.095	1.536	2.857	0

图5 多因素logistic回归分析曲线 a. De Ritis比值预测28 d病死率的ROC曲线; b.使用DCA评价De Ritis比值的有效性

Fig.5 Multivariate logistic regression analysis curve a. ROC curves of De Ritis for predicting 28-day mortality; b. DCA for evaluating De Ritis effectiveness

图6 限制性立方样条回归模型分析 a.模型1表示未调整分析；b.模型2包括性别、年龄和体重指数的调整；c.模型3包含模型2的变量,并进一步调整了其他因素,如种族、RR、MAP、HR、SOFA评分、SIRS评分、APSⅢ评分、SAPSⅡ评分、WBC、RBC、BUN、Scr、PCO2、钾、钠、pH和PO2。

Fig.6 Restricted cubic splines regression model for De Ritis a. Model 1 represents the unadjusted analysis; b. Model 2 involves adjustments for sex, age, and BMI; c. Model 3 includes the variables from Model 2 and further adjusts for additional factors such as race, RR, MAP, HR, SOFA score, SIRS score, APSⅢ score, SAPSⅡ score, WHC, RBC, BUN, Scr, PCO2, potassium, sodium, pH, and PO2.

表3 亚组分析

Tab.3 Subgroup analysis for De Ritis

项目	例数	百分比(%)	死亡风险	95% $C I$		$P$ 值	交互作用 $P$ 值
项目	例数	百分比(%)	死亡风险	下限	上限	$P$ 值	交互作用 $P$ 值
总数	1 674	100	1.15	1.08	1.22	<0.01
年龄(岁)
<65 ≥65	493 1 181	29.5 70.5	1.34 1.3	0.91 1.1	1.97 1.55	0.133 0.003	0.888
肝硬化
否是	1 587 87	94.8 5.2	1.34 1.58	1.14 0.8	1.58 3.12	<0.01 0.191	0.633
急性肾衰竭
否是	948 726	56.6 43.4	1.45 1.22	1.14 0.99	1.83 1.51	0.002 0.057	0.291
心力衰竭
否是	1 012 662	60.5 39.5	1.36 1.32	1.1 1.05	1.68 1.65	0.005 0.019	0.842
冠心病
否是	911 763	54.4 45.6	1.51 1.21	1.2 0.97	1.89 1.51	<0.01 0.09	0.17
SOFA
0	1 040	62.1	1.29	1.02	1.65	0.036
1	552	33	1.16	0.9	1.49	0.245	0.775
2	82	4.9	1.12	0.74	1.69	0.599
Charlson
0	127	7.6	1.62	0.69	3.79	0.266
1	311	18.6	1.64	1	2.69	0.051	0.531
2	1 236	73.8	1.25	1.05	1.48	0.01
APACHE Ⅱ
0	161	9.6	1.61	0.63	4.07	0.319
1	813	48.6	1.28	0.97	1.69	0.077	0.739
2	564	33.7	1.22	0.96	1.54	0.103
3	136	8.1	1.02	0.7	1.48	0.913
机械通气
否是	690 984	41.2 58.8	1.64 1.16	1.17 0.97	2.29 1.38	0.004 0.112	0.071

表3 亚组分析

Tab.3 Subgroup analysis for De Ritis

项目	例数	百分比(%)	死亡风险	95% $C I$		$P$ 值	交互作用 $P$ 值
项目	例数	百分比(%)	死亡风险	下限	上限	$P$ 值	交互作用 $P$ 值
总数	1 674	100	1.15	1.08	1.22	<0.01
年龄(岁)
<65 ≥65	493 1 181	29.5 70.5	1.34 1.3	0.91 1.1	1.97 1.55	0.133 0.003	0.888
肝硬化
否是	1 587 87	94.8 5.2	1.34 1.58	1.14 0.8	1.58 3.12	<0.01 0.191	0.633
急性肾衰竭
否是	948 726	56.6 43.4	1.45 1.22	1.14 0.99	1.83 1.51	0.002 0.057	0.291
心力衰竭
否是	1 012 662	60.5 39.5	1.36 1.32	1.1 1.05	1.68 1.65	0.005 0.019	0.842
冠心病
否是	911 763	54.4 45.6	1.51 1.21	1.2 0.97	1.89 1.51	<0.01 0.09	0.17
SOFA
0	1 040	62.1	1.29	1.02	1.65	0.036
1	552	33	1.16	0.9	1.49	0.245	0.775
2	82	4.9	1.12	0.74	1.69	0.599
Charlson
0	127	7.6	1.62	0.69	3.79	0.266
1	311	18.6	1.64	1	2.69	0.051	0.531
2	1 236	73.8	1.25	1.05	1.48	0.01
APACHE Ⅱ
0	161	9.6	1.61	0.63	4.07	0.319
1	813	48.6	1.28	0.97	1.69	0.077	0.739
2	564	33.7	1.22	0.96	1.54	0.103
3	136	8.1	1.02	0.7	1.48	0.913
机械通气
否是	690 984	41.2 58.8	1.64 1.16	1.17 0.97	2.29 1.38	0.004 0.112	0.071

参考文献 27

[1]	Boursin P, Paternotte S, Dercy B, et al. Semantics, epidemiology and semiology of stroke[J]. Soins, 2018, 63(828): 24-27.doi: 10.1016/j.soin.2018.06.008.
[2]	Battaglini D, Robba C, Lopes Da Silva A, et al. Brain-heart interaction after acute ischemic stroke[J]. Crit Care, 2020, 24(1): 163.doi: 10.1186/s13054-020-02885-8.
[3]	Chen Z, Venkat P, Seyfried D, et al. Brain-heart interaction: Cardiac complications after stroke[J]. Circ Res, 2017, 121(4): 451-468.doi: 10.1161/circresaha.117.311170. pmid: 28775014
[4]	Fan X, Cao J, Li M, et al. Stroke related brain-heart crosstalk: Pathophysiology, clinical implications, and underlying mechanisms[J]. Adv Sci (Weinh), 2024, 11(14): e2307698.doi: 10.1002/advs.202307698.
[5]	Sposato LA, Hilz MJ, Aspberg S, et al. Post-stroke cardiovascular complications and neurogenic cardiac injury: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 76(23): 2768-85.doi: 10.1016/j.jacc.2020.10.009. pmid: 33272372
[6]	Trefts E, Gannon M, Wasserman DH. The liver[J]. Curr Biol, 2017, 27(21): R1147-R1151. doi: 10.1016/j.cub.2017.09.019.
[7]	Liu H, Ding C, Hu L, et al. The association between AST/ALT ratio and all-cause and cardiovascular mortality in patients with hypertension[J]. Medicine, 2021, 100(31): e26693.doi: 10.1097/md.0000000000026693.
[8]	Djakpo DK, Wang ZQ, Shrestha M. The significance of transaminase ratio (AST/ALT) in acute myocardial infarction[J]. Arch Med Sci Atheroscler Dis, 2020, 5: e279-e83.doi: 10.5114/amsad.2020.103028.
[9]	Weng SF, Kai J, Guha IN, et al. The value of aspartate aminotransferase and alanine aminotransferase in cardiovascular disease risk assessment[J]. Open Heart, 2015, 2(1): e000272.doi: 10.1136/openhrt-2015-000272.
[10]	Chen W, Wang W, Zhou L, et al. Elevated AST/ALT ratio is associated with all-cause mortality and cancer incident[J]. J Clin Lab Anal, 2022, 36(5): e24356.doi: 10.1002/jcla.24356.
[11]	Knittelfelder O, Delago D, Jakse G, et al. The AST/ALT (De Ritis) ratio predicts survival in patients with oral and oropharyngeal cancer[J]. Diagnostics (Basel), 2020, 10(11):973. doi: 10.3390/diagnostics10110973.
[12]	Li L, Zeng Q, Xue N, et al. A nomogram based on aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio to predict prognosis after surgery in gastric cancer patients[J]. Cancer Control, 2020, 27(1): 1073274820954458.doi: 10.1177/1073274820954458.
[13]	Zhou J, He Z, Ma S, et al. AST/ALT ratio as a significant predictor of the incidence risk of prostate cancer[J]. Cancer Med, 2020, 9(15): 5672-5677.doi: 10.1002/cam4.3086.
[14]	Luo J, Yu F, Zhou H, et al. AST/ALT ratio is an independent risk factor for diabetic retinopathy: A cross-sectional study[J]. Medicine (Baltimore), 2024, 103(26): e38583.doi: 10.1097/md.0000000000038583.
[15]	Balling M, Nordestgaard BG, Varbo A, et al. Small dense low-density lipoprotein cholesterol and ischemic stroke[J]. Ann Neurol, 2023, 93(5): 952-964.doi: 10.1002/ana.26598.
[16]	Qie R, Liu L, Zhang D, et al. Dose-response association between high-density lipoprotein cholesterol and stroke: A systematic review and meta-analysis of prospective cohort studies[J]. Prev Chronic Dis, 2021, 18: E45.doi: 10.5888/pcd18.200278. pmid: 33988499
[17]	El-Sayed OS, Alnajjar AZ, Arafa A, et al. Association between risk of ischemic stroke and liver enzymes levels: A systematic review and meta-analysis[J]. BMC Neurol, 2025, 25(1): 18. doi: 10.1186/s12883-024-03875-x. pmid: 39806288
[18]	Jayaraj RL, Azimullah S, Beiram R, et al. Neuroinflammation: Friend and foe for ischemic stroke[J]. J Neuroinflammation, 2019, 16(1): 142.doi: 10.1186/s12974-019-1516-2.
[19]	殷越, 马一铭, 万晓红. 白细胞介素-1家族在缺血性脑卒中中的研究进展[J]. 中国现代医生, 2025, 63(17): 104-108.
[20]	Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease[J]. Oxid Med Cell Longev, 2019, 2019: 7092151.doi: 10.1155/2019/7092151.
[21]	张滕飞, 巩婷, 王黎, 等. 氧化应激在缺血性脑卒中病理进程中的作用[J]. 生命的化学, 2025, 45(6): 1063-1068.doi: 10.13488/j.smhx.20250062.
[22]	García N, Zazueta C, Aguilera-Aguirre L. Oxidative stress and inflammation in cardiovascular disease[J]. Oxid Med Cell Longev, 2017: 5853238.doi: 10.1155/2017/5853238.
[23]	Willard SS, Koochekpour S. Glutamate, glutamate receptors, and downstream signaling pathways[J]. Int J Biol Sci, 2013, 9(9): 948-959.doi: 10.7150/ijbs.6426. pmid: 24155668
[24]	Campos F, Rodríguez-Yáñez M, Castellanos M, et al. Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels[J]. Clin Sci (Lond), 2011, 121(1): 11-17.doi: 10.1042/cs20100427. pmid: 21265738
[25]	Gao F, Chen C, Lu J, et al. De Ritis ratio (AST/ALT) as an independent predictor of poor outcome in patients with acute ischemic stroke[J]. Neuropsychiatr Dis Treat, 2017, 13: 1551-1557.doi: 10.2147/ndt.S139316.
[26]	Castillo J, Dávalos A, Naveiro J, et al. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke[J]. Stroke, 1996, 27(6): 1060-1065.doi: 10.1161/01.str.27.6.1060. pmid: 8650715
[27]	Teichberg VI, Cohen-Kashi-Malina K, Cooper I, et al. Homeostasis of glutamate in brain fluids: An accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies[J]. Neuroscience, 2009, 158(1): 301-308.doi: 10.1016/j.neuroscience.2008.02.075. pmid: 18423998